-
Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.
Chemical research in toxicology 20170515
-
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.
Toxicological sciences : an official journal of the Society of Toxicology 20140101
-
Glucocorticoid-dependent expression of O(6)-methylguanine-DNA methyltransferase gene modulates dacarbazine-induced hepatotoxicity in mice.
The Journal of pharmacology and experimental therapeutics 20100601
-
Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites.
Molecular cancer research : MCR 20090601
-
Cerebellar dysfunction caused by procarbazine and consumption of excessive amount of bananas.
Pediatric blood & cancer 20080601
-
Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma.
Cancer treatment reviews 20080601
-
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080501
-
The 'old drug' dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas.
Investigational new drugs 20080401
-
Influence of therapy on the antioxidant status in patients with melanoma.
Journal of clinical pharmacy and therapeutics 20080401
-
Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies.
Cancer chemotherapy and pharmacology 20080301
-
Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/c-Jun NH2-terminal kinase activation in human melanoma cells.
The Journal of pharmacology and experimental therapeutics 20080301
-
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080220
-
Multicenter phase II study of chemoimmunotherapy in the treatment of metastatic melanoma.
Anti-cancer drugs 20080201
-
Hodgkin lymphoma presenting with various immunologic abnormalities, including autoimmune hepatitis, Hashimoto's thyroiditis, autoimmune hemolytic anemia, and immune thrombocytopenia.
Clinical lymphoma & myeloma 20080201
-
Unexpected clinical outcome in a patient with liver and brain metastasis from melanoma.
Anticancer research 20080101
-
The management of desmoids in patients with familial adenomatous polyposis (FAP).
Acta chirurgica Iugoslavica 20080101
-
CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.
European journal of clinical investigation 20071101
-
Comparison of a treatment strategy combining CCI-779 plus DTIC versus DTIC monotreatment in human melanoma in SCID mice.
The Journal of investigative dermatology 20071001
-
Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
Annals of oncology : official journal of the European Society for Medical Oncology 20071001
-
Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases.
Cancer 20070915
-
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070901
-
Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group.
Journal of cancer research and clinical oncology 20070701
-
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.
The journal of gene medicine 20070601
-
Hemorrhagic cystitis in a patient receiving conventional doses of dacarbazine for metastatic malignant melanoma: case report and review of the literature.
Clinical therapeutics 20070601
-
Single-agent interleukin-2 in the treatment of metastatic melanoma.
Current oncology (Toronto, Ont.) 20070201
-
Resection in the popliteal fossa for metastatic melanoma.
World journal of surgical oncology 20070101
-
Serum VEGF-C is associated with metastatic site in patients with malignant melanoma.
Acta oncologica (Stockholm, Sweden) 20070101
-
Adjuvant chemotherapy with doxorubicin and dacarbazine has no effect in recurrence-free survival of malignant phyllodes tumors of the breast.
The breast journal 20070101
-
Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
Oncology 20070101
-
Alkylating benzamides with melanoma cytotoxicity: experimental chemotherapy in a mouse melanoma model.
Melanoma research 20061201
-
Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
European journal of cancer (Oxford, England : 1990) 20061101
-
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20061010
-
Intralesional therapy of metastatic spreading melanoma with beta-interferon.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 20060901
-
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20060701
-
[Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma].
Annales de dermatologie et de venereologie 20060201
-
Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
Acta oncologica (Stockholm, Sweden) 20060101
-
Long-term survival in metastatic melanoma patients treated with sequential biochemotherapy: report of a Phase II study.
Cancer investigation 20060101
-
Artesunate in the treatment of metastatic uveal melanoma--first experiences.
Oncology reports 20051201
-
Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor.
Molecular cancer therapeutics 20051201
-
Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
The British journal of dermatology 20051101
-
A retrospective study of biochemotherapy for metastatic melanoma: the importance of dose intensity.
Cancer biotherapy & radiopharmaceuticals 20051001
-
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050920
-
Sarcomatoid renal cell carcinoma with a chromophobe component producing beta-human chorionic gonadotropin.
International journal of urology : official journal of the Japanese Urological Association 20050901
-
Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
Melanoma research 20050801
-
Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050801
-
Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model.
The Journal of investigative dermatology 20050801
-
Deficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents through G2-M cell cycle arrest.
International journal of oncology 20050601
-
Combined chemoimmunotherapy of metastatic melanoma: a single institution experience.
Melanoma research 20050601
-
Clusterin regulates drug-resistance in melanoma cells.
The Journal of investigative dermatology 20050601
-
Amelanotic malignant melanoma of the esophagus: report of a patient with recurrence successfully treated with chemoendocrine therapy.
International journal of clinical oncology 20050601
-
Functional erythropoietin autocrine loop in melanoma.
The American journal of pathology 20050301
-
Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 20041201
-
The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.
Melanoma research 20041201
-
Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.
Melanoma research 20041201
-
Serum bcl-2 and survivin levels in melanoma.
Melanoma research 20041201
-
A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy.
Molecular cancer therapeutics 20041201
-
Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040601
-
Activity of irinotecan, cisplatin and dacarbazine (CPD) combination in previously treated patients with advanced colorectal carcinoma.
Experimental oncology 20040601
-
Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations.
DNA repair 20040401
-
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040315
-
Correspondence re: DC Lev et al., Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther, 2003;2(8):753-63.
Molecular cancer therapeutics 20040301
-
[Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma].
Voprosy onkologii 20040101
-
O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma.
British journal of cancer 20031020
-
On the effect of biochemotherapy in metastatic malignant melanoma: an immunopathological evaluation.
Melanoma research 20030801
-
Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy.
Molecular cancer therapeutics 20030801
-
Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme.
Anti-cancer drugs 20030701
-
Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.
The Journal of investigative dermatology 20030601
-
Metastatic melanoma presenting as cardiac mass and hemobilia.
The American journal of the medical sciences 20030301
-
Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme.
British journal of cancer 20030224
-
Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer.
International journal of cancer 20030220
-
Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma.
British journal of cancer 20030113
-
Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo.
The Journal of investigative dermatology 20030101
-
IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.
Clinical & experimental metastasis 20030101
-
Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha.
Cancer immunology, immunotherapy : CII 20021201
-
Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
Cancer immunology, immunotherapy : CII 20021001
-
Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study.
American journal of clinical oncology 20021001
-
Analysis of O(6)-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy.
Melanoma research 20020801
-
Successful palliation of stenosing anorectal melanoma by intratumoral injections with natural interferon-beta.
Melanoma research 20020801
-
The role of glucocorticoids in the treatment of fulminant hepatitis induced by dacarbazine.
Anti-cancer drugs 20020201
-
Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine.
Cancer 20020101
-
Phase II trial of Paclitaxel and Dacarbazine with filgrastim administration in advanced malignant melanoma.
Cancer investigation 20020101
-
Docetaxel in combination with dacarbazine in patients with advanced melanoma.
Oncology 20020101
-
[Correlation between functional capability and phenotypic characteristics of peripheral blood lymphocytes in patients with malignant melanoma].
Glas. Srpska akademija nauka i umetnosti. Odeljenje medicinskih nauka 20020101
-
Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation.
Clinical cancer research : an official journal of the American Association for Cancer Research 20011201
-
Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.
Annals of oncology : official journal of the European Society for Medical Oncology 20010801
-
Dacarbazine-induced carotid artery and deep venous thrombosis in a patient with leiomyosarcoma: case report.
Journal of chemotherapy (Florence, Italy) 20010401
-
Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials.
Melanoma research 20010201
-
Therapeutic implications of the kinetics of immunomodulation during single or combined treatment of melanoma patients with dacarbazine and interferon-alpha.
Neoplasma 20010101
-
Dacarbazine DTIC and carboplatin as an outpatient treatment for disseminated malignant melanoma.
Anticancer research 20010101
-
Inhibition of melanoma growth and metastasis by combination with (-)-epigallocatechin-3-gallate and dacarbazine in mice.
Journal of cellular biochemistry 20010101
-
Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Cancer 20001215
-
Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase.
Carcinogenesis 20001001
-
Toxicity, mutation frequency and mutation spectrum induced by dacarbazine in CHO cells expressing different levels of O(6)-methylguanine-DNA methyltransferase.
Mutation research 20000214
-
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20000101
-
Chemotherapy for desmoid tumors in association with familial adenomatous polyposis.
Diseases of the colon and rectum 19970701
-
Phase I trial of dacarbazine with cyclophosphamide, carmustine, etoposide, and autologous stem-cell transplantation in patients with lymphoma and multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 19940901
-
FIVB plus GM-CSF in metastatic colorectal cancer.
Investigational new drugs 19940101
-
A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors.
Investigational new drugs 19930101
-
Dana-Farber Cancer Institute studies in advanced sarcoma.
Seminars in oncology 19900201
-
[Hepatic veno-occlusive disease caused by Deticene: a cause of acute hypovolemic shock].
Annales francaises d'anesthesie et de reanimation 19900101
-
Hepatic vascular toxicity of dacarbazine (DTIC): not a rare complication.
Hepatology (Baltimore, Md.) 19890501
-
Fatal hepatic vascular toxicity of DTIC. Is it really a rare event?
Cancer 19880515
-
[Ifosfamide treatment for children with malignant tumor].
Gan to kagaku ryoho. Cancer & chemotherapy 19871201
-
Allergy-induced hepatic toxicity associated with dacarbazine.
Cancer treatment reports 19870201
-
Peripheral DTIC neurotoxicity: a case report.
Cancer chemotherapy and pharmacology 19870101
-
[DTIC: effect on fibrinolysis and thrombocyte function].
Onkologie 19861001
-
Pathophysiological aspects of dacarbazine-induced human liver damage.
Hepato-gastroenterology 19851201
-
[Budd-Chiari syndrome following dacarbazine therapy of malignant melanoma--an avoidable complication?].
Zeitschrift fur Hautkrankheiten 19850615
-
Single-dose dacarbazine and dactinomycin in advanced malignant melanoma.
Cancer treatment reports 19850101
-
Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.
Journal of surgical oncology 19841201
-
Phase I trial of intermittent high-dose dacarbazine.
Cancer treatment reports 19840301
-
Acute liver dystrophy with thrombosis of hepatic veins: a fatal complication of dacarbazine treatment.
Cancer treatment reports 19830901
-
Mitomycin-associated renal failure. Case report and review.
Archives of internal medicine 19830401
-
[Dacarbazine in malignant melanoma. Rare, severe side-effect: Budd-Chiari-syndrome (author's transl)].
Zeitschrift fur Hautkrankheiten 19820701
-
[Budd-Chiari syndrome in DTIC therapy].
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 19820101
-
Hepatic vascular lesions associated with dacarbazine treatment.
British medical journal (Clinical research ed.) 19810530
-
[Veno-occlusive syndrome with acute liver dystrophy following decarbazine therapy of malignant melanoma (author's transl)].
Klinische Wochenschrift 19810302
-
Symptoms of occult brain metastases initiated by systemic Dacarbazine (DTIC-DOME) therapy in melanoma patients.
Clinical oncology 19801201
-
[Dacarbazine (DTIC) therapy and the Budd-Chiari syndrome].
MMW, Munchener medizinische Wochenschrift 19800523
-
Hepatic veno-occlusive disease due to DTIC.
Cancer 19800515
-
[Budd-Chiari syndrome during treatment with dacarbazine (DTIC) (author's transl)].
Deutsche medizinische Wochenschrift (1946) 19800215
-
Acute hepatic vein thrombosis occurring during therapy for Hodgkin's disease: a case report.
Cancer 19791201
-
Hepatic failure in a patient treated with dacarbazine (DTIC) for malignant melanoma.
Journal of cancer research and clinical oncology 19790101
-
High incidence of cardiomyopathy in children treated with adriamycin and DTIC in combination chemotherapy.
Cancer treatment reports 19771201
-
Neuraxonal dystrophy of the brain in patients receiving antineoplastic chemotherapy.
Acta neuropathologica 19770331
-
Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin.
Cancer 19751101
-
Carcinogenicity of the antineoplastic agent, 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide, and its metabolites in rats.
Journal of the National Cancer Institute 19750401
-
Central nervous system complications after combination treatment with adriamycin (NSC-123127) and 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).
Cancer chemotherapy reports 19740101